Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Overview 8
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics under Development by Companies 10
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Products under Development by Companies 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development 14
ArmaGen Technologies, Inc. 14
biOasis Technologies Inc. 15
Fate Therapeutics, Inc. 16
Green Cross Corporation 17
JCR Pharmaceuticals Co., Ltd. 18
Sangamo BioSciences, Inc. 19
Shire Plc 20
Synageva BioPharma Corp. 21
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AGT-182 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FT-1050 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gene Therapy to Target Iduronate 2-Sulfatase for Hunter Syndrome - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idursulfase - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
idursulfase - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
JR-032 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MTf-I2S - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MTfp-I2S - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Next Generation biologics for Pompe, Fabry and Hunter - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SHP-631 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Recent Pipeline Updates 42
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects 46
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development Milestones 47
Featured News & Press Releases 47
Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial 47
Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome 47
Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation 48
Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome 49
Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria 50
Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 50
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press 51
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome 51
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase 52
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), H1 2015 8
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by ArmaGen Technologies, Inc., H1 2015 14
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by biOasis Technologies Inc., H1 2015 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Fate Therapeutics, Inc., H1 2015 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Green Cross Corporation, H1 2015 17
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2015 18
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Sangamo BioSciences, Inc., H1 2015 19
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Shire Plc, H1 2015 20
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Synageva BioPharma Corp., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 42
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects, H1 2015 46